Andrew Cheng

President and CEO

Andrew Cheng (President and CEO) filed 13 Form 4 reports in the past 24 months (0 purchases, 13 sales), most often in AKRO. The largest single filing was $2.0M of AKRO (37,837 sh across 3 lots, as filed), executed Jun 10 2025. Data as of Nov 8 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 13 sells

Median delay

–

measured on stock purchases

Volume, ttmiDollar value disclosed in the trailing twelve months

$16.0M

shares × price, as filed

Last traded

Oct 10 2025

Filed Oct 14 2025

Open performance→

Volume by month

Buys $0 Sells $16.0M

Shares × price, as filed · by filing month · past 24 months

Most traded names

AKRO AKRO 0 buys · 13 sells 13 filings

Recent filings

AKROSALE Akero Therapeutics, Inc. View filing → $1.6M
30,000 sh × $53.98
Exec Oct 10 2025
Filed Oct 14 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $1.3M
29,842 sh across 2 lots
Exec Sep 10 2025
Filed Sep 12 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $1.4M
29,600 sh across 2 lots
Exec Aug 11 2025
Filed Aug 13 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $1.5M
30,000 sh across 2 lots
Exec Jul 10 2025
Filed Jul 11 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $363K
6,620 sh × $54.84
Exec Jun 18 2025
Filed Jun 20 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $2.0M
37,837 sh across 3 lots
Exec Jun 10 2025
Filed Jun 12 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $1.2M
30,000 sh across 2 lots
Exec May 12 2025
Filed May 13 2025 · 5:30 PM ET AKROSALE Akero Therapeutics, Inc. View filing → $1.1M
30,000 sh × $35.23
Exec Apr 10 2025
Filed Apr 11 2025 · 5:30 PM ET More filings →